AAAAAA

   
Results: 1-8 |
Results: 8
High remission rate in acute myeloblastic leukemia with only two days of chemotherapy
Authors: Preisler, HD Venugopal, P Gregory, SA Adler, S Gezer, S Hsu, WT Manson, S Larson, A Jajeh, A Slvinick, D Galvez, A
Citation: Hd. Preisler et al., High remission rate in acute myeloblastic leukemia with only two days of chemotherapy, LEUK LYMPH, 41(3-4), 2001, pp. 333-336
Significance of tissue laminin P-1 elastase and fibronectin levels in transitional cell carcinoma of the bladder
Authors: Kirkali, G Tuzel, E Guler, C Gezer, S Kirkali, Z
Citation: G. Kirkali et al., Significance of tissue laminin P-1 elastase and fibronectin levels in transitional cell carcinoma of the bladder, EUR UROL, 39(3), 2001, pp. 292-299
Successful establishment of long-term bone marrow cultures in 103 patientswith myelodysplastic syndromes
Authors: Alvi, S Shaher, A Shetty, V Henderson, B Dangerfield, B Zorat, F Joshi, L Anthwal, S Lisak, L Little, L Gezer, S Mundle, S Reddy, PL Allampallam, K Huang, XK Galili, N Borok, RZ Raza, A
Citation: S. Alvi et al., Successful establishment of long-term bone marrow cultures in 103 patientswith myelodysplastic syndromes, LEUK RES, 25(11), 2001, pp. 941-954
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
Authors: Raza, A Meyer, P Dutt, D Zorat, F Lisak, L Nascimben, F du Randt, M Kaspar, C Goldberg, C Loew, J Dar, S Gezer, S Venugopal, P Zeldis, J
Citation: A. Raza et al., Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes, BLOOD, 98(4), 2001, pp. 958-965
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine)
Authors: Preisler, HD Venugopal, P Gregory, SA Hsu, WT Loew, J Adler, S Gezer, S Creech, S Galvez, A Slivnick, D Andric, T Larson, RA Jajeh, A
Citation: Hd. Preisler et al., Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine), LEUK RES, 24(8), 2000, pp. 671-680
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
Authors: Raza, A Qawi, H Lisak, L Andric, T Dar, S Andrews, C Venugopal, P Gezer, S Gregory, S Loew, J Robin, E Rifkin, S Hsu, WT Huang, RW
Citation: A. Raza et al., Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone, BLOOD, 95(5), 2000, pp. 1580-1587
Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis
Authors: Dar, S Mundle, S Andric, T Qawi, H Shetty, V Reza, S Mativi, BY Allampallam, K Ali, A Venugopal, P Gezer, S Broady-Robinson, L Cartlidge, J Showel, M Hussaini, S Ragasa, D Ali, I Chaudhry, A Waggoner, S Lisak, L Huang, RW Raza, A
Citation: S. Dar et al., Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis, EUR J HAEMA, 62(2), 1999, pp. 90-94
Biologic characteristics of patients with hypocellular myelodysplastic syndromes
Authors: Goyal, R Qawi, H Ali, I Dar, S Mundle, S Shetty, V Mativi, Y Allampallam, K Lisak, L Loew, J Venugopal, P Gezer, S Robin, E Rifkin, S Raza, A
Citation: R. Goyal et al., Biologic characteristics of patients with hypocellular myelodysplastic syndromes, LEUK RES, 23(4), 1999, pp. 357-364
Risultati: 1-8 |